The Impact of COVID-19 on Patients With Neuromyelitis Optica Spectrum Disorder Beyond Infection Risk

There is an increasing need for better understanding of the impact of coronavirus disease 2019 (COVID-19) on patients with neuromyelitis optica spectrum disorder (NMOSD). A few pilot studies have investigated COVID-19 infections in NMOSD, but few studies have addressed disease activity and immune status of these patients during the pandemic. We carried out a cross-sectional study to examine immune status, relapses, and COVID-19 infections in a cohort of NMOSD patients using an electronic patient registry (MSNMOBase) for multiple sclerosis and related disorders. An online questionnaire was administered to all NMOSD patients in the registry from January 1, 2011, to June 1, 2020. Clinical demographic characteristics, immune status, relapses, treatments, COVID-19 infections, and preventive measures were evaluated. Of the 752 registered patients, 535 (71.1%) with qualified data were included. A total of 486 used preventive therapies during the pandemic, including mycophenolate mofetil (71.2%), azathioprine (13.3%), and other immunosuppressants (6.4%). Neither median immune cell counts nor immunoglobulin levels (p > 0.05) were significantly different between patients with or without immunosuppression. During the pandemic, no patients were diagnosed with COVID-19, and the majority (>95%) took one or more effective protective measures (e.g., wearing a mask and social distancing). However, a significantly higher annualized relapse rate (ARR) was observed in the 33 patients with treatment interruptions due to the pandemic compared to before it (p < 0.05), whereas ARR changes were not found in patients with continuous treatments or those without treatments (p > 0.05). Interruption frequency was significantly higher in patients with relapses compared to those without (34.9 vs. 15.7%, p < 0.01). For stable NMOSD patients during the pandemic, the risk of relapse due to treatment interruption may be higher than the risk of COVID-19 infection when protective measures are used, and continuous relapse-prevention treatments may be necessary.

[1]  Russell S. Peak,et al.  Part 2: , 2020, Journal of Neural Transmission.

[2]  H. Hartung,et al.  Targeting B Cells to Modify MS, NMOSD, and MOGAD , 2020, Neurology: Neuroimmunology & Neuroinflammation.

[3]  H. Hartung,et al.  Targeting B Cells to Modify MS, NMOSD, and MOGAD , 2020, Neurology: Neuroimmunology & Neuroinflammation.

[4]  C. Louapre,et al.  COVID-19 infection in NMO/SD patients: a French survey , 2020, Journal of Neurology.

[5]  C. Louapre,et al.  Beyond COVID-19: DO MS/NMO-SD patients treated with anti-CD20 therapies develop SARS-CoV2 antibodies? , 2020, Multiple Sclerosis and Related Disorders.

[6]  L. Cui,et al.  Prediction of long-term disability in Chinese patients with multiple sclerosis: A prospective cohort study. , 2020, Multiple sclerosis and related disorders.

[7]  E. Ciampi,et al.  COVID-19 in MS and NMOSD: A multicentric online national survey in Chile , 2020, Multiple Sclerosis and Related Disorders.

[8]  Sharon J Peacock,et al.  Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. , 2020, JAMA.

[9]  Y. Bao,et al.  Prevalence of and Risk Factors Associated With Mental Health Symptoms Among the General Population in China During the Coronavirus Disease 2019 Pandemic , 2020, JAMA network open.

[10]  M. Han,et al.  The impact of COVID-19 on patients with neuromyelitis optica spectrum disorder; a pilot study. , 2020, Multiple sclerosis and related disorders.

[11]  F. Shi,et al.  Risk of COVID-19 infection in MS and neuromyelitis optica spectrum disorders , 2020, Neurology: Neuroimmunology & Neuroinflammation.

[12]  A. Serra,et al.  Current and emerging therapeutics for neuromyelitis optica spectrum disorder: Relevance to the COVID-19 pandemic , 2020, Multiple Sclerosis and Related Disorders.

[13]  M. Sahraian,et al.  Evaluation of COVID-19 infection in patients with Neuromyelitis optica spectrum disorder (NMOSD): A report from Iran , 2020, Multiple Sclerosis and Related Disorders.

[14]  J. Pačes,et al.  COVID-19 and the immune system. , 2020, Physiological research.

[15]  R. Baric,et al.  DNA vaccine protection against SARS-CoV-2 in rhesus macaques , 2020, Science.

[16]  J. Imitola,et al.  Mild COVID-19 infection despite chronic B cell depletion in a patient with aquaporin-4-positive neuromyelitis optica spectrum disorder. , 2020, Multiple Sclerosis and Related Disorders.

[17]  Cezmi A Akdis,et al.  Immune response to SARS‐CoV‐2 and mechanisms of immunopathological changes in COVID‐19 , 2020, Allergy.

[18]  R. Kream,et al.  An Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development , 2020, Medical science monitor : international medical journal of experimental and clinical research.

[19]  Zacharias E. Andreadakis,et al.  The COVID-19 vaccine development landscape , 2020, Nature Reviews Drug Discovery.

[20]  Xuetao Cao COVID-19: immunopathology and its implications for therapy , 2020, Nature Reviews Immunology.

[21]  F. Claas,et al.  HLA association in MOG-IgG– and AQP4-IgG–related disorders of the CNS in the Dutch population , 2020, Neurology: Neuroimmunology & Neuroinflammation.

[22]  L. Cui,et al.  Long-term efficacy of mycophenolate mofetil in myelin oligodendrocyte glycoprotein antibody-associated disorders , 2020, Neurology: Neuroimmunology & Neuroinflammation.

[23]  T. Palaga,et al.  Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. , 2020, Asian Pacific journal of allergy and immunology.

[24]  G. Leung,et al.  Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study , 2020, The Lancet.

[25]  Jing Zhao,et al.  Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia , 2020, The New England journal of medicine.

[26]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[27]  Jacqueline Palace,et al.  International multicenter examination of MOG antibody assays , 2020, Neurology: Neuroimmunology & Neuroinflammation.

[28]  A. Espiritu,et al.  Efficacy and tolerability of azathioprine for neuromyelitis optica spectrum disorder: A systematic review and meta-analysis. , 2019, Multiple sclerosis and related disorders.

[29]  K. Chu,et al.  Pneumonia in hospitalized neurologic patients: trends in pathogen distribution and antibiotic susceptibility , 2019, Antimicrobial resistance and infection control.

[30]  Chun-juan Wang,et al.  Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder , 2018, Journal of the Neurological Sciences.

[31]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[32]  H. Ren,et al.  Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and cyclophosphamide among patients with neuromyelitis optica spectrum disorder: A prospective cohort study , 2016, Journal of the Neurological Sciences.

[33]  F. Paul,et al.  MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin , 2016, Journal of Neuroinflammation.

[34]  Y. Itoyama,et al.  Impact of the Great East Japan Earthquake in 2011 on MS and NMOSD: a study in Sendai, Japan , 2016, Journal of Neurology, Neurosurgery & Psychiatry.

[35]  C. Tan International consensus diagnostic criteria for neuromyelitis optica spectrum disorders , 2016, Neurology.

[36]  A. Traboulsee,et al.  International consensus diagnostic criteria for neuromyelitis optica spectrum disorders , 2015, Neurology.

[37]  Zhengqi Lu,et al.  Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders , 2014, Neurology.

[38]  Jacqueline A Palace,et al.  Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. , 2014, JAMA neurology.

[39]  K. Fujihara,et al.  Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders , 2014, Neurology.

[40]  S. Yaghi,et al.  The effect of war stress on multiple sclerosis exacerbations and radiological disease activity , 2010, Journal of the Neurological Sciences.

[41]  Ariel Miller,et al.  Impact of exposure to war stress on exacerbations of multiple sclerosis , 2008, Annals of neurology.

[42]  David C. Mohr,et al.  A temporal framework for understanding the effects of stressful life events on inflammation in patients with multiple sclerosis , 2006, Brain, Behavior, and Immunity.

[43]  T. Patterson,et al.  Severely threatening events and marked life difficulties preceding onset or exacerbation of multiple sclerosis. , 1989, Journal of neurology, neurosurgery, and psychiatry.

[44]  J. Kurtzke Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[45]  R. C. Macridis A review , 1963 .

[46]  E. Palmquist Report from Iran. , 1955, Pediatrics.

[47]  L. Cui,et al.  Acute epileptic seizures in myelin oligodendrocyte glycoprotein encephalomyelitis and neuromyelitis optica spectrum disorder: A comparative cohort study. , 2019, Multiple sclerosis and related disorders.

[48]  H. Hakimzadeh,et al.  Part 1 , 2011 .

[49]  V. Preedy,et al.  Prospective Cohort Study , 2010 .

[50]  J. Manson,et al.  Prospective Study of , 2007 .